Last $5.01 USD
Change Today -0.13 / -2.53%
Volume 46.3K
CCXI On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 08/20/14 All times are local (Market data is delayed by at least 15 minutes).

chemocentryx inc (CCXI) Snapshot

Open
$5.10
Previous Close
$5.14
Day High
$5.20
Day Low
$5.00
52 Week High
08/22/13 - $12.51
52 Week Low
11/7/13 - $4.57
Market Cap
217.1M
Average Volume 10 Days
71.8K
EPS TTM
$-0.99
Shares Outstanding
43.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHEMOCENTRYX INC (CCXI)

Related News

No related news articles were found.

chemocentryx inc (CCXI) Related Businessweek News

No Related Businessweek News Found

chemocentryx inc (CCXI) Details

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates under clinical stage include Vercirnon, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe Crohn’s disease; CCX140 that is in Phase II clinical trial for the treatment of patients with diabetic nephropathy, a form of kidney disease; and CCX354 that completed a Phase II proof-of-concept clinical trial for the treatment of rheumatoid arthritis. The company’s drug candidates also comprise CCX168, which is in a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody associated renal vasculitis; CCX872 that is under Phase I clinical development targeting CCR2 for expanded indications of renal disease; and CCX507, a de novo wholly-owned CCR9 inhibitor, which is in Phase I clinical trials for inflammatory bowel disease and related disorders. Its preclinical stage programs comprise CCX650, an orally active drug for the treatment of glioblastoma multiforme; CCR4 inhibitor for atopic dermatitis; CCX6239, an orally administered CCR4 antagonist with potential utility in the treatment of atopic dermatitis; CCR6 inhibitor for autoimmune diseases; and CXCR6 inhibitor for liver diseases. The company was founded in 1997 and is headquartered in Mountain View, California.

60 Employees
Last Reported Date: 03/14/14
Founded in 1997

chemocentryx inc (CCXI) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $510.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $372.2K
Senior Vice President Medical & Clinical Affa...
Total Annual Compensation: $369.4K
Chief Business Officer and Treasurer
Total Annual Compensation: $354.5K
Compensation as of Fiscal Year 2013.

chemocentryx inc (CCXI) Key Developments

ChemoCentryx, Inc. Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

ChemoCentryx, Inc. announced consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company's loss from operations was $12.4 million compared with $9.6 million a year ago. Net loss was $12.3 million or $0.28 per basic and diluted share compared with $9.5 million or $0.23 per basic and diluted share a year ago. There was no revenue recognized for the three months ended June 30, 2014, compared to $1.9 million recognized in the same period in 2013. The decrease in revenue from 2013 to 2014 was primarily due to funding of clinical support in 2013 from former partner, GlaxoSmithKline, for CCX168, a C5aR inhibitor, for the treatment of ANCA-associated vasculitis. For the six months, the company's loss from operations was $24.1 million compared with $19.9 million a year ago. Net loss was $23.8 million or $0.55 per basic and diluted share compared with $19.7 million or $0.51 per basic and diluted share a year ago.

ChemoCentryx, Inc. to Report Q2, 2014 Results on Aug 05, 2014

ChemoCentryx, Inc. announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Aug 05, 2014

ChemoCentryx, Inc., Q2 2014 Earnings Call, Aug 05, 2014

ChemoCentryx, Inc., Q2 2014 Earnings Call, Aug 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CCXI:US $5.01 USD -0.13

CCXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $55.06 USD -0.23
Biogen Idec Inc $342.58 USD -3.26
Bristol-Myers Squibb Co $50.04 USD -0.26
Incyte Corp $51.66 USD -0.46
Takeda Pharmaceutical Co Ltd ¥4,687 JPY -4.00
View Industry Companies
 

Industry Analysis

CCXI

Industry Average

Valuation CCXI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 99.0x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 54.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHEMOCENTRYX INC, please visit www.chemocentryx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.